{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
hydrocortisone butyrate
to a specific field?
Status:
Possibly Marketed Outside US
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Butyric acid (butanoic acid) belongs to a group of short-chain fatty acids and is thought to play several beneficial roles in the gastrointestinal tract. The butyric anion is easily absorbed by enteric cells and used as a main source of energy. Moreover, butyric acid is an important regulator of colonocyte proliferation and apoptosis, gastrointestinal tract motility and bacterial microflora composition in addition to its involvement in many other processes including immunoregulation and anti-inflammatory activity. Butyric acid shows a protective effect in inflammatory
response secondary to inflammatory bowel diseases. A beneficial effect of butyric acid as one constituent
of a multifaceted mechanism modulating gastrointestinal
function has also been stressed in patients with the stoma
and coexisting constipation. Butyric acid supplementation
combined with the use of probiotics should be adopted
as one of the basic therapeutic strategies in this
patient group, preceding treatment with laxatives. Sodium butyrate in the form of enemas (combined
in a mixture with A-300 silicon dioxide) may be a successful
method of therapeutic management in patients
with radiation proctitis. Sodium butyrate may also prevent diarrhea
through an increased passive absorption of water in the
colon and its effects on the gut microflora.
Status:
Possibly Marketed Outside US
First approved in 2018
Source:
ARONAMIN GOLD by OASIS TRADING
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Riboflavin butyrate (a vitamin B2 derivative used widely in Japan) is often an ingredient of multivitamin complexes, used for relief of following symptoms: stomatitis, glossitis, perleche, cheilitis, rough skin, acne, dermatitis, eczema, rash, sores. It is a supply of Vitamins B2 and B6 in the following situations: physical fatigue, pregnancy/lactation, decline of physical strength during or after illness.
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2013)
Source URL:
First approved in 2013
Source:
21 CFR 347
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2012)
Source URL:
First approved in 2012
Source:
505G(a)(3)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
ANDA208784
(1995)
Source URL:
First approved in 1995
Source:
ANDA208784
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
ANDA208784
(1995)
Source URL:
First approved in 1995
Source:
ANDA208784
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 1995
Source:
ANDA078730
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Ethyl butyrate (C6H12O2) also known as ethyl butanoate, or butyric ether is an ester. Ethyl butyrate is used as an extract, as a flavoring or perfume, and as a solvent. It is a colorless liquid with a banana, orange or pineapple odor, and it is flammable. Exposure to ethyl butyrate can irritate the skin, eye, nose and throat. Applications include: artificial flavoring resembling orange juice or pineapple in alcoholic beverages, as a solvent in perfumes, and as a plasticizer for cellulose.
Status:
Possibly Marketed Outside US
Source:
Atrimustine by Onbio Inc.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Atrimustine [bestrabucil, busramustine, KM 2210, kregan], a conjugate of estradiol and chlorambucil, is a DNA antagonist that was developed by Kureha Corporation (Japan). Atrimustine is an antineoplastic drug that was used for the treatment of breast cancer, non-Hodgkin's lymphoma, as well as Graft-versus-host disease. Side effects of atrimustine in clinical trials included vaginal bleeding and gynecomastia. Atrimustine reached preregistration in Japan for the treatment of cancer, however, its development has been discontinued.
Status:
Possibly Marketed Outside US
Source:
Kanamycin, amphomycin, and hydrocortisone ointment
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Conditions:
Amphomycin is a natural antibacterial lipopeptide initially reported by researchers at Bristol-Myers in 1953 from Streptomyces canus. Lipopeptides are cyclic depsipeptides with a peptidyl side chain capped with a saturated alkyl tail. They preferentially target Gram-positive bacteria and may be useful against drug resistant strains. Amphomycin is closely related to a number of "lost" antibiotics, such as aspartocin, crystallomycin, glumamycin, friulimicin, laspartocin, tsushimycin and zaomycin. Interest in amphomycin was re-awakened with the discovery of friulimicin activity against antibiotic resistant strains. Whole cell analysis by solid-state NMR indicates that in vivo mode of action for amphomycin is complex. While the downstream effect of purine biosynthesis inhibition by amphomycin is unknown, presumably it would directly alter the overall metabolism of bacteria.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Hydrocortisone caproate is a synthetic steroid hormone and 21-O-hexanoyl derivative of hydrocortisone. Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. Food and Drug Administration (FDA) in 1956 and withdrawn from marketing in 1999. Hydrocortisone caproate acts by binding to progesterone receptors in the uterus, ovaries, breasts and in the central nervous system. These receptors exist in 2 isoforms, PR-A and PR-B. Hydrocortisone caproate binding to these receptors ultimately leads to regulation of gene transcription. This results in an anti-inflammatory effect which blunts the proinflammatory state that occurs with the initiation of labor and maintains uterine quiescence by stabilizing progesterone acting on the myometrium. Following intramuscular injection, approximately 50% of hydroxyprogesterone caproate metabolites are eliminated in the feces, while approximately 30% of metabolites are eliminated in the urine. Injection site pain is the most common adverse effect associated with hydroxyprogesterone caproate. Other commonly reported adverse effects include injection site swelling, urticaria, pruritus, injection site pruritus, nausea, injection site nodule, and diarrhea.
